Introduction

Biologics have revolutionized the therapy of moderate-to-severe plaque psoriasis. Despite their greater efficacy over conventional systemic therapies their high cost has represented a burden for health-care systems, which limited their use. The availability of biosimilars at low cost is changing the place in therapy of biologics for psoriasis.

Areas covered

The role of TNF- α inhibitors in the management of plaque psoriasis, their efficacy and safety profile are presented. Phase 3 clinical trials and real-life data from the use of TNF- α inhibitor biosimilars in the treatment of plaque psoriasis are also reviewed in detail. Furthermore, arguments in favor of the use of TNF- α inhibitor biosimilars as a first-line therapy in moderate-to-severe plaque psoriasis are discussed.

Expert opinion

An increasing amount of data show that biosimilars represent a safe and effective alternative to the originator biologics. In the face of ever-increasing health-care costs, switching to biosimilars and starting naïve patients on the best-value biologic can reduce expenditure for patients and payers while maintaining a high-quality care. Moreover, as the cost of biosimilars is approaching the cost of conventional systemic treatments, TNF-α inhibitors biosimilars may represent a first-line systemic treatment for psoriasis patients because they are effective and safe.

中文翻译：

---

TNF-α 抑制剂生物仿制药作为中重度慢性斑块状银屑病的一线全身治疗。

简介

生物制剂彻底改变了中重度斑块状银屑病的治疗方法。尽管它们比传统全身疗法更有效，但它们的高成本已经成为医疗保健系统的负担，这限制了它们的使用。低成本生物仿制药的可用性正在改变生物制剂治疗银屑病的地位。

覆盖区域

介绍了 TNF-α 抑制剂在治疗斑块状银屑病中的作用、其有效性和安全性。还详细回顾了使用 TNF-α 抑制剂生物仿制药治疗斑块状银屑病的 3 期临床试验和真实数据。此外，还讨论了支持使用 TNF-α 抑制剂生物仿制药作为中重度斑块状银屑病一线治疗的论点。

专家意见

越来越多的数据表明，生物仿制药是原研生物制剂的一种安全有效的替代品。面对不断增加的医疗保健成本，改用生物仿制药并开始使用最有价值的生物制剂可以减少患者和付款人的支出，同时保持高质量的护理。此外，随着生物仿制药的成本接近常规全身治疗的成本，TNF-α抑制剂生物仿制药可能代表银屑病患者的一线全身治疗，因为它们有效且安全。